P. Paka

A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease

Michael A. Yamin, S. Friedman, I. Goldberg, 2018, World journal of nephrology.

Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.

M. Duh, R. Bhak, M. Dersarkissian, 2022, Leukemia & lymphoma.

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

L. Sansbury, S. Sapra, W. Sopwith, 2022, The European Journal of Health Economics.

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

L. Sansbury, S. Sapra, W. Sopwith, 2022, The European Journal of Health Economics.

Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database

X. Leleu, S. Landi, P. Paka, 2023, European journal of haematology.

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study.

O. Decaux, P. Moreau, H. Avet-Loiseau, 2023, Haematologica.

P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY

X. Leleu, M. Roussel, P. Paka, 2022, HemaSphere.

Perioperative glucose management and outcomes in liver transplant recipients: A qualitative systematic review

A. Barritt, R. Dupuis, R. Lee, 2018, World journal of transplantation.